title: The Silence in Hoch et al.'s Commentary about the Rationale for and Objective(s) of Canada's Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers' Dollars.
authors.affiliation: Health Research Methodology (HRM) Program, McMaster University, Hamilton, Canada, heatherpauline@me.com.
authors.forename: Heather
authors.initials: H
authors.lastname: McDonald
authors.forename: Cathy
authors.initials: C
authors.lastname: Charles
authors.forename: Laurie
authors.initials: L
authors.lastname: Elit
authors.forename: Amiram
authors.initials: A
authors.lastname: Gafni
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D002170:Canada; D030881:Disclosure; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics; D040841:Resource Allocation; D012941:Social Responsibility; D013660:Taxes / Q000191:economics; D013673:Technology Assessment, Biomedical / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents